Livionex, a Los Gatos, CA-based biotech company addressing unmet medical needs in Periodontitis, Cataracts and Herpes Simplex Virus, raised $4M in Series A funding at a $180m valuation.
Backers included unnamed private investors and family offices.
Founded in 2009, Livionex is advancing a solution that can potentially prevent and treat prevalent diseases, such as gingivitis, periodontitis, cataracts, and herpes simplex virus.
The company has also launched its oral care line, LIVFRESH, as a dentist-recommended, clinically proven solution for eliminating plaque, which uses edible ingredients on the FDA’s GRAS list. It is currently being evaluated by the FDA to become an oral care product to treat both gingivitis and periodontitis (terminal gum disease).
Livionex is scheduling a Phase 2C study to help its eye-drops become the first non-invasive treatment to improve vision in early-to-moderate cataract patients.
The company intends to use the funds to accelerate the growth of their technology that is advancing treatments for gum disease, cataracts, and herpes simplex virus and market penetration of LIVFRESH in the US and Asian markets.